Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[4][5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.
[6] It is on the World Health Organization's List of Essential Medicines.
[7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
This drug article relating to the respiratory system is a stub.